WEBULL

Viatris (VTRS): Assessing Valuation After a Recent Share Price Rebound

Simply Wall St · 1d ago

Viatris (VTRS) has been quietly grinding higher, with the stock up about 5% this week and roughly 9% over the past month, even as its year to date return remains negative.

See our latest analysis for Viatris.

That recent climb sits against a bumpier backdrop, with the share price still showing a negative year to date return even as the 3 year total shareholder return is positive. This suggests momentum is tentatively rebuilding as sentiment toward Viatris shifts.

If Viatris has you rethinking healthcare exposure, it might be a good moment to explore other opportunities across healthcare stocks and see how they stack up on growth and resilience.

With shares still down for the year but trading at a steep intrinsic discount and only a modest gap to analyst targets, investors now face a key question: is this a genuine value opportunity, or is future growth already priced in?

Most Popular Narrative Narrative: 6.4% Undervalued

With Viatris last closing at $11.65 against a narrative fair value of $12.44, the story leans toward cautious upside built on steadier margins.

The analysts have a consensus price target of $11.429 for Viatris based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $14.0, and the most bearish reporting a price target of just $8.0.

Read the complete narrative.

Want to see what kind of margin turnaround and earnings reset could justify this richer future multiple? The projections behind this fair value may surprise you.

Result: Fair Value of $12.44 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, sustained price pressure in key markets, along with setbacks from facility remediation or integration challenges, could quickly undermine the improving margin and cash flow story.

Find out about the key risks to this Viatris narrative.

Build Your Own Viatris Narrative

If you see the story differently or want to test your own assumptions against the numbers, you can build a custom view in just minutes, Do it your way.

A great starting point for your Viatris research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.

Looking for more investment ideas?

Before the next move in Viatris plays out, you can put your capital to work by scanning fresh opportunities with focused stock screens built around quality, growth and income.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.